CTOS 2018

Approximately 70% of patients were administered anthracyclines as a primary therapy across patient datasets from France, Germany, Spain, and Italy.

Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski.

Durable responses to treatment with atezolizumab in advanced alveolar soft part sarcoma were seen across a phase 2 study.

Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.

Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.

But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.

The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.

A subset of patients experienced sustained clinical benefit and at least some objective tumor response.

Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.

Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.